


Adenocarcinoma gastroesofágico resecable

MATTERHORN

FLOT + Durvalumab/placebo perioperatorio



Statistical Endpoints and Definitions

5

Primary endpoint:

- **Event-Free Survival (EFS)*:** Time from randomization to event or death (tested at 41% maturity)


Key secondary endpoints:

- **Overall Survival (OS)†:** Interim analysis at 34% maturity with minimal α -spend (0.01%); final OS ongoing ($\alpha=4.99\%$)
- **Path Complete Response (pCR)*:** No residual viable tumor in the primary site and nodes at surgery; reported at ESMO 2023¹


Secondary endpoint

- **Disease-Free Survival (DFS):** Time to disease recurrence or death in participants with R0 resection

Multiple testing procedure and alpha allocation




Eficacia – Supervivencia libre de evento




Secondary Endpoint of Overall Survival (OS)

10




Seguridad

Most common AEs of any grade*



Most common maximum Grade 3 or 4 AEs†



Conclusions

- **Durvalumab with FLOT significantly improved EFS vs FLOT alone** in resectable gastric and GEJ adenocarcinoma
- **EFS benefit was consistent** across subgroups and geographic regions
- No new safety concerns were identified
- OS data are encouraging; final OS analysis pending



A copy of these slides and an infographic plain language summary of this presentation can be accessed via the QR code above

MATTERHORN supports global adoption of perioperative durvalumab with FLOT as a new standard for patients with localized gastric and gastroesophageal adenocarcinoma

